Evotec Announces Horizon' - Next Inflection in Its Strategic Transformation to Accelerate Growth and Promote Agility Horizon advances multi-stage transformation initiated with Priority Reset in 2024 and establishes new o

Announces Horizon' - Next Inflection in Its Strategic Transformation to Accelerate Growth and Promote Agility

Hamburg, Germany, March 10, 2026 -

Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced Horizon', the next phase in its multi-stage transformation

initiative. Horizon advances the company's evolution by implementing a new and focused operating model built across the three pillars

of operations, science and commercial execution. This model is designed to generate above market growth and enhance operating leverage

in an environment of normalized demand and increased expectations on scientific and operational performance, building on the Priority

Reset in 2024 and the articulation of strategic levers for mid-term value creation in 2025.

Horizon will simplify organizational structures,

reorganize Evotec's global expertise into new, focused Centers of Excellence and align the company footprint to support more disciplined

execution in high-value segments of the drug discovery and preclinical development market.

Dr. Christian Wojczewski, Chief Executive

Officer of Evotec, said:

"Horizon represents the next step in Evotec's

structured transformation to position the company for sustainable, high-quality growth. Following the disciplined cost actions implemented

over the past two years and the strategic priorities we set in 2025, we are now transforming our operating model. This will enable deeper

integration, faster decision making and greater agility for our customers and partners. Horizon positions Evotec for stronger performance

through 2027 and lays the foundation for further optimization and intelligent scaling toward 2030."

Horizon marks an important step to position Evotec

for the next phase in the evolution of the global drug discovery and pre-clinical development market, driven by deeper scientific excellence

and advances in data science, automation and AI. It represents a building phase after which the company will operate with a more disciplined

cost base, a higher-value technology-driven revenue mix, improved operating margins and a platform capable of delivering sustainable

and profitable growth. Operational streamlining will increase agility and responsiveness and will enable faster execution, particularly

within Evotec's drug and preclinical development (D&PD) business.

Horizon accelerates delivery on Evotec's

four strategic levers for mid-term value creation:

As part of the transformation, Evotec plans to

further optimize its global footprint, reduced from 19 to 14 sites between 2024 and 2025, to 10 sites over the next two years. The footprint

optimization will be accompanied by a workforce adjustment affecting up to 800 positions across all locations. Centers of Excellence

will enable a centralized innovation infrastructure by concentrating key areas of expertise. This focused model is designed to strengthen

scientific depth, enhance cross-disciplinary collaboration and support growth in high-value therapeutic and technology-driven areas.

Implementation of these measures has been initiated,

with first operational effects anticipated in the second half of 2026. Horizon is expected to be substantially implemented by the end

of 2027, taking into account phased workforce adjustments in accordance with local legal requirements. The organizational changes and

associated charges that Evotec expects to incur are subject to a number of assumptions, including local legal requirements. The company

is committed to a transparent process and does not expect material disruption to ongoing customer programs.

Paul Hitchin, Chief Financial Officer of Evotec,

"From a financial perspective, Horizon

represents a fundamental realignment of our operating model and cost structure. We are simplifying our cost base, reallocating resources

toward higher-value, intellectual property-driven programs and improving operating leverage across the business to create value for our

stakeholders. While 2026 will be a transition year, our objective is a structurally more focused organization with enhanced long-term

profitability and strengthened cash generation through 2027 and beyond."

Financial Framework and Medium-Term Outlook

Considering the start of Horizon and the transition

year expected in 2026, Evotec is revising its medium-term financial framework to reflect a phased trajectory from 2026 through 2030.

The revised framework incorporates the timing

of restructuring measures and the continued development of the revenue mix across Evotec's two business segments.

Preliminary FY 2025 Performance (Unaudited)

To provide transparency as part of the updated

framework, Evotec is sharing preliminary, unaudited full-year 2025 financial figures, subject to completion of year-end closing and audit

For full-year 2025, Evotec expects results to

fall within its previously communicated guidance ranges:

Evotec will report final fourth quarter and full-year

2025 results on April 8, 2026.

Discovery & Preclinical Development (D&PD)

Preliminary unaudited revenues for the D&PD

segment are expected to amount to approximately 529 million ( 540 million CER), representing a year-on-year decrease

of 13 %. Adjusted EBITDA for the segment is expected to amount to approximately - 12 million (- 5 million CER).

Just - Evotec Biologics (JEB)

Preliminary unaudited revenues for the JEB segment

are expected to amount to approximately 259 million ( 271 million CER), representing a year-on-year increase of 40 %.

Adjusted EBITDA contribution from JEB is expected to amount to approximately 53 million ( 57 million CER).

Horizon Financial Impact and 2026 Guidance

Horizon is expected to be substantially completed

by the end of 2027. 2026 will represent a transition year, with meaningful operational improvements anticipated to become increasingly

visible in the second half.

Evotec expects total run-rate cost savings of

approximately 75 million from the structural Horizon measures by the end of 2027 of which a positive contribution will be already

To implement Horizon, Evotec expects total cash

restructuring charges of approximately 100 million over the 2026-2028 period. There are also expected to be non-cash components

related to asset impairments.

Evotec enters 2026 with annualized savings of

approximately 60 million realized in 2025, fully embedded in its structurally lower operating cost and driven by improved capital

discipline and a progressively more technology-driven revenue mix and base. These structural cost reductions, combined with improved

utilization and a shift toward higher-margin technology and platform-based activities, are expected to enhance operating leverage and

support sustained margin expansion from 2027 onward.

For full-year 2026, Evotec expects:

Medium-Term Framework 2026-2030

Evotec is providing a new medium-term framework

for 2026-2030 to consider the timing and impact of Horizon while maintaining its growth ambition. The framework reflects a phased trajectory.

The framework reflects:

This phased approach defines a clear trajectory

from operational reset, through transition, to sustainable margin expansion and scalable growth by 2030. Further details on the medium-term

framework will be provided during the final fourth quarter and full-year 2025 reporting on April 8, 2026.

Evotec will host a webcast and conference call

today at 3 p.m. CET / 2 p.m. GMT / 10 a.m. EDT.

To join the audio webcast and to access the presentation

slides, please register via this link. The on-demand replay of the webcast will be available under the same link after the event

Conference Call Details

To join the conference call, please pre-register

via this link. You will receive a confirmation email with dedicated dial-in details such as telephone number, access code and

PIN to access the call. A simultaneous slide presentation for participants dialing in via phone is available under this link.

Evotec is a life science company that is pioneering

the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies,

we accelerate the journey from concept to cure - faster, smarter, and with greater precision.Our expertise spans small molecules,